| Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis S Clark, F Lanni, D Marinova, E Rayner, C Martin, A Williams The Journal of infectious diseases 216 (5), 525-533, 2017 | 45 | 2017 |
| Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis A Chandran, K Williams, T Mendum, G Stewart, S Clark, S Zadi, F Lanni, ... Scientific reports 9 (1), 17791, 2019 | 31 | 2019 |
| A rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: macrolide case study F Kaya, JP Ernest, K LoMauro, M Gengenbacher, A Madani, WW Aragaw, ... Antimicrobial agents and chemotherapy 66 (3), e02212-21, 2022 | 19 | 2022 |
| Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis F Levillain, H Kim, KW Kwon, S Clark, F Cia, W Malaga, F Lanni, P Brodin, ... Vaccine 38 (6), 1416-1423, 2020 | 16 | 2020 |
| Comparison of pellicle and shake flask-grown BCG strains by quality control assays and protection studies M Fitzpatrick, MM Ho, S Clark, B Dagg, B Khatri, F Lanni, A Williams, ... Tuberculosis 114, 47-53, 2019 | 14 | 2019 |
| Adaptation to the intracellular environment of primary human macrophages influences drug susceptibility of Mycobacterium tuberculosis F Lanni, GJ Wijnant, M Xie, P Osiecki, V Dartois, JP Sarathy Tuberculosis 139, 102318, 2023 | 6 | 2023 |
| The potential of microdialysis to estimate rifampicin concentrations in the lung of guinea pigs F Lanni, N Burton, D Harris, S Fotheringham, S Clark, O Skinner, N Wiblin, ... PloS one 16 (1), e0245922, 2021 | 6 | 2021 |
| Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates AD White, AC Tran, L Sibley, C Sarfas, AL Morrison, S Lawrence, ... Frontiers in Immunology 14, 1246826, 2023 | 4 | 2023 |
| A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease F Lanni, R Antilus Sainte, M Hansen Jr, P Parigi, F Kaya, K LoMauro, ... Antimicrobial Agents and Chemotherapy 67 (12), e00671-23, 2023 | 2 | 2023 |
| Heterogeneity in immune cell composition is associated with Mycobacterium tuberculosis replication at the granuloma level SK Cooper, DF Ackart, F Lanni, M Henao-Tamayo, GB Anderson, ... Frontiers in Immunology 15, 1427472, 2024 | 1 | 2024 |
| Tuberculous Meningitis: an Update on the Pathogenesis and Neuroimmunology S Hokeness, F Lanni, J Glycenfer, A Obregon-Henao, M Henao-Tamayo Current Tropical Medicine Reports 11 (1), 1-10, 2024 | 1 | 2024 |
| Determination of the pharmacokinetics and pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a cross-over cynomolgus macaque model of Mycobacterium … L Sibley, AD White, C Sarfas, J Gullick, F Gleeson, F Lanni, S Clark, ... Pharmaceutics 14 (12), 2666, 2022 | | 2022 |
| Determination of Organ Specific Pharmacokinetic Data for the Anti-tuberculosis Drugs in Guinea Pigs Using Microdialysis FR Lanni PQDT-Global, 2019 | | 2019 |
| Pharmacokinetic Modelling of Rifampicin, Isoniazid, Pyrazinamide, Linezolid, and Rifabutin in N Abdelgawad, JC Miranda, S Wasserman, F Lanni, R Antilus-Sainte, ... (1) Division of Clinical Pharmacology, Department of Medicine, University of …, 1 | | 1 |